CME in Minutes: Education in Oncology & Hematology

Please visit answersincme.com/860/104092969-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO; and Jesus Berdeja, MD. In this activity, experts in hematology-oncology discuss the evolving role of cereblon E3 ligase modulators (CELMoDs) in patients with relapsed/refractory multiple myeloma (RRMM). Upon completion of this activity, participants should be better able to: Identify the role of CELMoDs in the treatment of patients with RRMM. Utilize evidence-based practical strategies for the management of key adverse events associated with CELMoDs in patients with RRMM. Apply key considerations to support the integration of CELMoDs into the treatment paradigm for patients with RRMM.

Please visit answersincme.com/860/2026-MC-002375-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO; and Krina Patel, MD, MSc. In this activity, experts in multiple myeloma discuss key treatment considerations and personalization strategies for anti-CD38 therapy. Upon completion of this activity, participants should be better able to: Evaluate the clinical implications of key data supporting anti-CD38–based regimens in patients with multiple myeloma (MM); Outline evidence-based strategies to manage toxicities associated with anti-CD38–based therapies; Identify key considerations for integrating anti-CD38 monoclonal antibodies into treatment plans for patients with MM; and Apply practical, patient-centered care considerations to optimize outcomes with anti-CD38 monoclonal antibodies for patients with MM.

Please visit answersincme.com/CJF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Manuel Rodriguez-Justo, MBBCh, MSc, MD, FRCPath; and Elizabeth Smyth, MD, FRCP. In this activity, experts in oncology and pathology discuss the impact of claudin 18.2 (CLDN18.2) tests and treatments for patients with advanced gastric or gastroesophageal junction cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for CLDN18.2 testing in patients with advanced gastric and gastroesophageal junction cancers (GC/GEJC); Review the potential clinical impact of emerging CLDN18.2-targeted antibody-drug conjugates (ADCs) for the treatment of GC/GEJC; and Outline evidence-based, emerging strategies to optimize outcomes in patients with advanced GC/GEJC.

Please visit answersincme.com/MSM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ritu Salani, MD; and Courtney Arn, CNP. In this activity, experts in gynecological oncology discuss antibody-drug conjugates (ADCs) in ovarian, cervical, and endometrial cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for using ADCs in previously treated patients with gynecologic cancers; Assess the safety and tolerability evidence for approved ADC therapies in gynecologic cancers; Formulate management strategies for adverse events associated with ADC treatment of ovarian, cervical, and endometrial cancers; and Outline patient-centered approaches to facilitate adherence with ADC therapy.

Please visit answersincme.com/WAY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Elizabeth O'Donnell, MD. In this activity, an expert in multi-cancer early detection (MCED) discusses strategies to apply MCED testing into everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the benefits and risks of MCED testing; and Outline patient-centered strategies to appropriately incorporate MCED testing into the primary care setting.

Please visit answersincme.com/860/cvdprostate-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michael Cookson, MD; Alicia Morgans, MD, MPH; and Avirup Guha, MD, MBBS, MPH, FAHA, FACC, FESC, FICOS. In this activity, experts in prostate cancer discuss cardiovascular risk in patients receiving androgen-deprivation therapy (ADT). Upon completion of this activity, participants should be better able to: Evaluate the impacts of prostate cancer and ADT on cardiovascular risk; Translate the latest research for cardiovascular management of patients on ADT to clinical practice; and Design personalized treatment approaches to optimize ADT across treatment settings.

Please visit answersincme.com/NHB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Zev Wainberg, MD. In this activity, an expert in oncology discusses the use of TROP2-directed antibody-drug conjugates (ADCs) across solid tumors. Upon completion of this activity, participants should be better able to: Review the rationale for targeting TROP2 with antibody-drug conjugates (ADCs) across tumor stages and settings; Evaluate the clinical profiles of available and emerging TROP-targeting ADCs across tumor stages and settings; and Apply evidence-based strategies to recognize and monitor treatment-related adverse events (TRAEs) associated with ADCs.

Please visit answersincme.com/KNY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Barbara Melosky, MD, FRCPC; and Alyson Chin, RN, BScN, MN-ACNP(A). In this activity, experts in lung cancer discuss the management of adverse events associated with tyrosine kinase inhibitor use in patients with ALK-positive metastatic non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Identify ALK tyrosine kinase inhibitor (TKI)–related adverse events (AEs) among patients with ALK-positive (ALK+) metastatic non–small-cell lung cancer (mNSCLC); Apply strategies to effectively monitor and manage ALK TKI–related AEs to enhance treatment adherence in patients with ALK+ mNSCLC; and Outline multidisciplinary, patient-centered strategies to optimize care for patients receiving ALK TKIs for ALK+ mNSCLC.

Please visit answersincme.com/RVH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vivien Brown, MDCM, CCFP, FCFP, MSCP. In this activity, an expert in menopause management in primary care discusses identification and treatment of menopause-related vasomotor symptoms (VMS). Upon completion of this activity, participants should be better able to: Integrate communication about menopause and VMS into routine patient encounters; Review treatment options for moderate to severe VMS, including NK receptor antagonists, with patients using a shared decision-making approach; and Formulate strategies for optimally monitoring patients who are receiving NK receptor antagonists for menopause-related VMS.

Please visit answersincme.com/JKK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alison J. Birtle, FRCP, FRCR, MD; and Niklas Klümper, MD. In this activity, experts in oncology discuss systemic therapies for locally advanced and metastatic urothelial carcinoma. Upon completion of this activity, participants should be better able to: Assess the evidence for recommended systemic treatment regimens for patients with LA/mUC in the context of treatment guidelines; Propose appropriate patient assessment strategies to guide systemic therapy decisions; and Formulate individualized treatment strategies to optimize outcomes for patients with LA/mUC using recommended first-line systemic treatments.

Please visit answersincme.com/NDX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tycel J. Phillips, MD and Steven Horwitz, MD. In this activity, experts in B-cell and T-cell lymphomas discuss EZH inhibitors for non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Discuss the rationale for EZH inhibitors in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL); Describe the clinical profiles of available and emerging EZH inhibitors; and Outline current and potential methods of optimizing EZH inhibitors in clinical practice based on available evidence.

Please visit answersincme.com/ZGK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Amer Zeidan, MBBS, MHS. In this activity, an expert in myelodysplastic syndromes (MDS) discusses approaches to optimize management of anemia in lower-risk MDS. Upon completion of this activity, participants should be better able to: Translate the latest clinical trial data to the management of patients with lower-risk MDS; Evaluate evidence-based strategies for optimizing the use of available agents in lower-risk MDS; and Design treatment plans that effectively sequence available therapies in patients with lower-risk MDS.

Please visit answersincme.com/XUG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sara A. Hurvitz, MD, FACP. In this activity, an expert in breast cancer discusses the evidence for TROP2-directed antibody-drug conjugates in metastatic triple-negative disease (mTNBC). Upon completion of this activity, participants should be better able to: Review the clinical impact of TROP2-directed antibody-drug conjugates (ADCs) for the management of mTNBC; Evaluate the clinical implications of the evidence exploring first-line use of TROP2 ADCs in combination with immunotherapy for mTNBC; and Develop an evidence-informed strategy that incorporates TROP2-directed ADCs and immunotherapy combinations into first-line management of mTNBC, where appropriate.

Please visit answersincme.com/GFY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vishal A. Patel, MD; and Jonathan S. Zager, MD, FACS, FSSO. In this activity, experts in cutaneous oncology discuss the evolving role of gene expression profiling (GEP) tests in refining risk assessment and supporting individualized, multidisciplinary management strategies for patients with melanoma. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using GEP tests to stratify the risk of disease progression in patients with cutaneous melanoma; Review the clinical evidence, including guideline-supported data, for GEP tests to stratify disease progression risk in patients with cutaneous melanoma; Formulate multidisciplinary strategies for incorporating the results of GEP tests into risk-based management of patients with cutaneous melanoma; and Outline patient-centered approaches to integrating GEP tests into the management of patients with cutaneous melanoma at risk of metastasis.

Please visit answersincme.com/860/103117485-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD and David Harpole, MD. In this activity, experts in EGFR-mutated advanced non–small-cell lung cancer (NSCLC) discuss current and emerging strategies for sequencing therapies beyond progression. Upon completion of this activity, participants should be better able to: Evaluate sequencing strategies for patients with advanced EGFR-mutated NSCLC following first-line progression, applying biologic insights and genomic testing to guide optimal therapy selection; and Discuss the role of emerging therapies in advanced EGFR-mutated NSCLC, applying insights from tumor biology to optimize sequential treatment decisions.

Please visit answersincme.com/860/2026-MC-002106-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by María-Victoria Mateos, MD, PhD; and Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO. In this activity, experts in multiple myeloma discuss evidence-based strategies to personalize frontline care with anti-CD38-based quadruplets in patients with newly diagnosed myeloma. Upon completion of this activity, participants should be better able to: Identify key clinical factors that inform tailored frontline treatment approaches in patients with NDMM; Evaluate the clinical implications of key data supporting evolving frontline treatment approaches with anti-CD38–based quadruplet regimens in patients with NDMM; and Outline evidence-based strategies to integrate emerging treatment approaches into the clinical workflow of patient care in NDMM.

Please visit answersincme.com/860/103117485-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD; and Benjamin Levy, MD, FASCO. In this activity, experts in EGFR-mutated advanced non–small-cell lung cancer (NSCLC) discuss how tumor biology and genomic reassessment can guide sequencing after first-line progression. Upon completion of this activity, participants should be better able to: Evaluate sequencing strategies for patients with advanced EGFR-mutated NSCLC following first-line progression, applying biologic insights and genomic testing to guide optimal therapy selection; and Discuss the role of emerging therapies in advanced EGFR-mutated NSCLC, applying insights from tumor biology to optimize sequential treatment decisions.

Please visit answersincme.com/860/101707775-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. [Presented by Erika Hamilton, MD, FASCO; Komal Jhaveri, MD, FACP, FASCO; and John Allen Piede, MD. In this activity, experts in breast cancer provide a practical, community-focused discussion on integrating ESR1 mutation testing, applying emerging data on novel endocrine therapies, such as SERDs, and personalizing treatment strategies for patients with HR+, HER2− advanced breast cancer. Upon completion of this activity, participants should be better able to: Integrate testing for ESR1 mutations at appropriate times into practice workflows in the treatment of patients with HR-positive, HER2-negative advanced breast cancer; Evaluate the clinical implications of the latest evidence for approved and late-stage emerging novel oral SERDs in patients with HR-positive, HER2-negative advanced breast cancer; and Apply multidisciplinary, patient-centered strategies for optimizing treatment outcomes with novel oral SERDs in patients with HR-positive, HER2-negative advanced breast cancer.

Please visit answersincme.com/860/101707775-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Erika Hamilton, MD, FASCO; Komal Jhaveri, MD, FACP, FASCO; and Eleonora Teplinsky, MD, FASCO. In this activity, experts in breast cancer provide a practical, community-focused discussion on integrating ESR1 mutation testing, applying emerging data on novel endocrine therapies, such as SERDs, and personalizing treatment strategies for patients with HR+, HER2− advanced breast cancer. Upon completion of this activity, participants should be better able to: Integrate testing for ESR1 mutations at appropriate times into practice workflows in the treatment of patients with HR-positive, HER2-negative advanced breast cancer; Evaluate the clinical implications of the latest evidence for approved and late-stage emerging novel oral SERDs in patients with HR-positive, HER2-negative advanced breast cancer; and Apply multidisciplinary, patient-centered strategies for optimizing treatment outcomes with novel oral SERDs in patients with HR-positive, HER2-negative advanced breast cancer.

Please visit answersincme.com/BXW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Katarzyna J. Jerzak, MD, MSc, FRCPC. In this activity, an expert in medical oncology reviews the optimal use of CDK4/6 inhibitors for the treatment of hormone receptor (HR)–positive/HER2-negative early and metastatic breast cancer based on the latest guidelines and long-term evidence. Upon completion of this activity, participants should be better able to: Define patient eligibility for CDK4/6 inhibitor therapy in hormone receptor (HR)–positive/HER2-negative early and metastatic breast cancer per the Research Excellence, Active Leadership (REAL) Canadian Breast Cancer Alliance recommendations; Evaluate long-term clinical evidence supporting CDK4/6 inhibitors with endocrine therapy in HR-positive/HER2-negative early and metastatic breast cancer; and Apply evidence-based, patient-centered strategies to optimize long-term management of HR-positive/HER2-negative early and metastatic breast cancer.